

Application No. 09/976,838

Amendments to the Claims

We claim:

1-10 (canceled).

11. (Previously presented) A method of treating Epstein Barr virus comprising the steps of administering to a patient a therapeutic amount of glycyrrhizic acid wherein the glycyrrhizic acid inhibits the transcription of viral latent genes of the Epstein Barr virus.

12. (Canceled)

13. (Previously presented) The method according to claim 11 wherein the dosage for a child is about 10mg to about 50 mg.

14. (Canceled)

15. (Previously presented) The method according to claim 11 wherein the dosage for an adult is about 50mg to about 1000 mg.

16. (Canceled)

Application No. 09/976,838

17. (Previously presented) The method according to claim 11 wherein the dosage is about 2.5 mg to about 50mg/kg.

18. (Canceled)

19. (Previously presented) The method according to claim 11 wherein the dosage is applied intranasally.

20. (Canceled)

21. (Previously presented) The method according to claim 11 wherein the dosage is applied intravenously.

22. (Canceled)

23. (Previously presented) The method according to claim 11 wherein the dosage is applied parenterally.

24. (Canceled)

Application No. 09/976,838

25. (Previously presented) A method of treating Epstein Barr virus according to claim 11 wherein the glycyrrhizic acid is in the form of a salt of glycyrrhizic acid.

26. (Canceled)

27. (Previously presented) A method of treating Epstein Barr comprising the steps of administering to the patient a therapeutic amount of the glycyrrhizic acid wherein the glycyrrhizic acid inhibits the expression of latent viral antigens of the Epstein Barr virus.

28. (Canceled)